Study which found full spectrum, high Cannabidiol treatment improved clinical symptoms in anxiety patients.
Conclusion:
Initial results from the open-label stage of this clinical trial demonstrated significant improvement of primary outcome assessments of anxiety, providing preliminary evidence that a full-spectrum, high-CBD product may be efficacious for treating anxiety with few side effects.
Patients quickly achieved and maintained ≥15% reduction of anxiety symptoms with most patients demonstrating clinically significant treatment response after 1 week of treatment.
Treatment response was demonstrated at a much lower dosage than a previous clinical trial using a single extracted CBD isolate product.
Secondary outcome assessments demonstrated improvements on measures of mood, sleep disturbance, quality of life and executive functioning following treatment.
A definitive assessment of the impact of this novel treatment on clinical symptoms and cognition will be ascertained in the ongoing double-blind, placebo-controlled stage.
